Spinoff Companies and Affiliates
- Relocated headquarters from Cleveland Clinic to Buffalo as a result of the recruitment of Andrei Gudkov, PhD, DSci, to Roswell Park as Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
- Founded in 2003 as a publicly traded drug discovery and development company
- Pursuing three key areas of research: biodefense for acute radiation syndrome, cancer treatment, and tissue protection
- Located at 73 High Street on the Buffalo Niagara Medical Campus
- Has strategic partnerships with the Cleveland Clinic, RPCI, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute
- More than 50 advanced research positions were relocated to Buffalo, between the company and the academic laboratory
- Currently employs 60 people
- Cleveland BioLabs subsidiary
- Will develop a portfolio of new pre-clinical drug candidates from the laboratory of Andrei Gudkov, PhD, DSci, Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
- Supported by investments from Rusnano, a Russian biotech fund
- Cleveland BioLabs and three other intellectual property owners — RPCI, Cleveland Clinic Foundation and Children’s Cancer Institute–Australia — will transfer intellectual property rights related to a specific portfolio of compounds to Panacela
- Cleveland BioLabs subsidiary
- Launched December 7, 2009 by Andrei Gudkov, PhD, DSci, Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
- Biomedical research organization engaged primarily in research and development of compounds, drugs, vaccines and other preventive and therapeutic materials relating to cancer, aging and age-associated diseases
Simulated Surgical Systems, LLC
- Founded in 2009 by Khurshid Guru, MD, Director of The Center for Robotic Surgery at RPCI, and Dr. Thenkurussi “Kesh” Kesavadas, PhD, Director of the University at Buffalo’s Virtual Reality Lab
- Focuses on development of training software and simulators to train surgeons in robot-assisted surgery
- Joint venture between Roswell Park and the University at Buffalo
- International trainees travel to Buffalo for training in robot-assisted surgery
- Founded in 2007 by Norma Nowak, PhD, Director of the DNA Microarray and Genomics Facility at Roswell Park
- Focuses on genetic testing services for the in-vitro diagnostics industry
- Expansion planned; expects to increase staff from 10 to 31 in three years
- Launched in August 2007 by James Mohler, MD, and Gary Smith PhD, Co-Leaders of the Prostate Program at Roswell Park
- Both were recruited to RPCI from the University of North Carolina/Chapel Hill – Dr. Mohler in 2003 and Dr. Smith in 2006
- Pioneering new therapeutic approaches for advanced prostate cancer, including therapies targeting cancer stem cells
- Founded by William Cance, MD, FACS, Chair of the Department of Surgical Oncology
- Developing a broad-based platform of investigational therapies for rare cancers
- Pre-clinical studies on the company’s lead compounds have been completed; CureFAKtor will soon launch Phase I clinical research studies
Photolitec, LLC
- Launched in January 2011 by Ravindra Pandey, PhD, Distinguished Member of the Department of Cell Stress Biology at RPCI
- Develops compounds used in photodynamic therapy (PDT) to identify cancer in medical imaging and treat cancer
- Supported by an investment from Zhejiang Hisun Pharmaceutical Co. Ltd, Zhejiang, China
- Launched in 2011 to commercialize the HSP 110 cancer and infectious disease therapeutic vaccine developed at Roswell Park over the last 18 years by John Subjeck, PhD, and Shawn Wang, PhD, Cell Stress Biology
- Broad platform technology to enhance immune recognition of cancer antigens and infectious disease antigens
- Nine issued patents protecting all cancer antigens and all infectious disease antigens
- Phase I clinical study IND approved January 2012
MimiVax
- Founded in 2011 by Robert Fenstermaker, MD, and Michael Ciesielski, PhD, Chair Neuro Oncology and Assistant Professor Neurosurgery, Nuero Oncology, respectively
- Focus on the commercialization of modified Survivin peptides as cancer immunotherapy
- Phase I clinical study initiated at Roswell Park in 2011
